Cadila Healthcare Ltd - 532321 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting dated July 12, 2021 with regard to Notice and information of 26th Annual General Meeting of the Company
Cadila Healthcare Q1 PAT seen up 63.9% YoY to Rs 744 cr: KRChoksey
Net Sales are expected to increase by 8.7 percent Y-o-Y (up 5.4 percent Q-o-Q) to Rs 3,956 crore, according to KRChoksey.
Zydus Cadila's Covid-19 vaccine approval likely in next few days: Report
On July 1, the company had sought emergency use approval of ZyCoV-D, its DNA vaccine against Covid-19 for those aged 12 years and above CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Change in Directorate
Re-appointment of Mr. Ganesh N. Nayak as the Executive Director of the Company for a period of three years, subject to approval of shareholders at the ensuing AGM. CADILA HEALTHCARE LTD. - 532321 - Shareholding for the Period Ended June 30, 2021
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here CADILA HEALTHCARE LTD. - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 Plasmid DNA vaccine
Last week, India's pharmaceutical major Zydus Cadila sought emergency use authorisation' for its invention plasmid DNA vaccine', which it calls ZyC
Zydus Cadila gets USFDA nod to market generic HIV infection treatment tablets
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, Zydus Cadila said in a statement. Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets